Not only biomedical mecca, but a beautiful area. I have relatives there.

Just a side note. At the bottom of article on Pfizer laboratories, it mentions:

C. Ichim used to be a member researcher there. From company PR last July:

You are correct, depending on what previous outlook you had.

The reality is becoming clearer and those who expect instant success will continue to be frustrated. If your outlook, based on the statements of the PRs over the past several months are that GLP studies are necessary for HemaX, dCellVax and all future INDs and that RGBP has clearly stated that none of their previous experiments on HemaX meet the GLP criteria, then the outlook now on GLP safety studies is a matter of weeks to months to complete for HemaX IND approval. That is established by companies own PRs.

Therefore, one should not predict or expect dCellVax to be "approved" for clinical studies at any moment, because the logical explanation is that dCellVax also is in need of further GLP studies and most likely Regen is finalizing an understanding with FDA on its dCellVax IND what the protocol for those studies need to be in order to pass FDA muster.

Flippers who want to actively trade something over the next 2 months most likely need to exit and go somewhere else.

Here, my opinion is that we are finally building the foundation of a real company. The concrete is being poured and while the reality of a future launch now is gaining more realistic with each week, the BIG PHARMA buyout to the moon is not on the near term radar in my opinion.

Even today's PR, which I welcome, is clear to state that the new facilities are for developmental experimentation and that the GLP studies will need to be contracted out.

A legitimate question.

Because the names from various scientists and companies overlap, we need to get down into the details for clarification.
Dr. WP Minn is not an employee of RGBP, but rather RGBP owns the patent for his research on dCellVax and Minn was the one conducting various pre-clinical experiments. He runs a research dept at a Univ, so he can set up various research for different products, companies etc without impeding progress. The key factor here is that if he wants to make money off his dCellVax research, dCellVax has to go forward as there are milestones to make.

Dr. Patel is only in an advisory counsel role, not direct research or employment of RGBP products.

Ichim is now a key player as he has sold some of his research and patent to RGBP, was hired by RGBP and has become chief scientific director. Once again, there are big incentives within RGBP that are on time deadlines, so the time is ticking for him to move things forward if he wants financial gains.

And his hiring is recent, patent acquisition a recent development while in the past he was collaborating on research.

So, the hopeful insight to this is that something fairly significant has taken place in order for the restructuring, payment, employment etc for Koos and Ichim to move into an employer/employee relationship with Ichim giving up rights to some of his research in return.

We hope that our reading of these events to be validated within the next few months. This is a make it or break it type of year for RGBP at the end of which we will have a much better feel as to future hope or inevitably postponement of success.

Low volume. No huge sell off or dumping as some predicted. Will we get another weekly PR tomorrow? Don't want to overly hope for one, but would be very interesting if there was.

10x is very possible given 2 or more INDs approved for human clinical trials, but I think 6 months from now is more realistic for that projection.

Heck, I'd be very happy with 5x the current price within the next 4-6 months because that would mean real progress will have been made and approved and once you get by the first and second, like dominoes, other great things might develop and who knows what the price might reach.

Still filling the gas tanks and building the rocket stages at this point in my opinion.

PR should let us know how this will progress.

My guess and it's only my opinion is that the HemaXellerate Safety trials will be set up with an established outside GLP company to conduct, since they have extensive protocols for what is to be done and the benchmarks etc. to evaluate. While it will be under the direction of either T. Ichim or WP Min, I suspect Ichim will be busy conducting further research testing on the other product lines and it might delay other INDs to have the safety tests done where their normal research is taking place.

WP Min is associated with University of Western Ontario
C. Ichim was at Univ of Toronto (link from 2013: My Science page

But I don't know where she or T. Ichim are performing their research.

Also agree the NEW4THIS job posting find is another piece of the puzzle. The tone seems to me to indicate we are not to anticipate a merger, but instead Regen itself becoming more a true scientific entity and company that will be collaborating with other GLP entities possibly for the actual safety test results and the lab assistant sounds to be a person preparing the subjects and gathering the tissue/cells needs for the testing.

Also encouraging as others have noted that the job description makes clear that this job description includes training others, so the workload the company is embarking on is too much for just the Ichims to perform - another good sign that more is taking place than what has been released in PRs so far.

In December of 2014, Regen had no one in house other than Koos getting direct payments and now the workload is too much for two full time scientists to handle, so that ad for more people means more work is going on, there is money to pay for the work and more material for future PRs.

All is good. I don't think we're going to land on the moon tomorrow, but the rocket is adding more stages and boosters so that when we launch, the trip will last longer and go farther.

No offense, BME. Everyone has their own views and opinions. As long as the exchanges are sincere and try to be objective and based in some type of fact, I have no problem.

I admit it irkes me when a PR comes out and someone posts multiple optimistic comments on immediate results that go against the very statements in the PR. Don't think that helps anyone.

Pax et bonum.

What would be the advantage or reason of saying that the next step is the need to commence a study instead of saying, "Regen has already begun the necessary safety trials."

Obviously, everyone would rather get the news that the trial was already underway, in progress, projected to have results by xyz than to hear that the next step is to commence the study. You can't say you need to commence something you've already commenced; it's objectively contradictory.

I'd very much rather they had said trials were underway, but I think it is to the long term benefit of all on this board that we strive to objectively figure out what's happening rather than wishful thinking projections that in the end discourage all new investors, disappoint those hoping for improbable and take away from the positive buildup this board could have in really sharing valuable projections, DD and research rather than improbable wishful best case scenarios.

Just my outlook since I'm not here to flip or convince someone else to sell when I want to buy or buy when I want to sell. Not that that is what you were doing, but certainly seems others on this board try to do.

Sorry, but disagree on you can state whatever you want in PRs. You may be able to say whatever you want on this board, but companies that outright lie in official public company PRs open themselves up to litigation and lawsuits that they most likely would lose.

PRs can contain wishful thinking, best scenario projections, overly optimistic guidances that the disclaimer will protect, but for instance, a company that said it had acquired $700,000 in funding that hadn't acquired any money would not be protected by a disclaimer note. Fraud is not protected by the disclaimer.

Why the attacK? Why spend so much time?

Not likely Jeff. The PR states:


Companies shouldn't be lying in PRs, so that can't say the next step is to commence (begin) the safety study if it was already in progress. That said, since this has been a long time coming, I certainly hope the place, needs, animals etc. for the safety clinical trials were already lined up so that safety trials can begin without delay. If not, we are back to incompetence issues.

However, I don't think the company was restructured and everyone hired merely for HemaX safety trials, so I think there is definitely more news to come.

And I agree with other post, besides HemaX, dCellVax and NR2F6, two other patents were acquired (one with pre-clinical data) within the past 2 months that might be material for future PRs as well. I think we are still in the stages of a planned piece by piece release of info on a more steady basis (at some point it won't be every week) in order to create ongoing interest (not blip and run), the inability of flippers to dump with great confidence, not knowing what next week's news might bring and new trust and transparency that the shareholders are going to be more informed now then in times past.

AIMO

Hope has returned. Will it be fulfilled? Only time will tell, but 2015 is off to a good start.

AIMO

I don't, but based on previous PRs over the past 2 years, I would expect the test to take a few weeks and then they wait to wait a specific time period to note any negative effects, toxicology etc before submitting.

My guesstimate is 3-4 months before they will submit data to FDA, so maybe we are looking at some July fireworks in my estimation.

Interesting post and yes, interesting fact that they collaborate on multiple treatments. Good news is that this ValloVax seems to be a vaccine, therefore not in direct competition with dCellVax. That said, the hiring of Ichim and WP Min both having money tied to shares that have value with milestones being reached, the knowledge they have from various studies and possibilities might end up in joint venture or merger of companies whose complimentary treatments prove successful. Since each treatment would have to be controlled by different patents owned by companies and not Ichim now, he wouldn't be able to steal the secrets of one to give to the other. The more research he does on similar and complimentary research, the better I hope.

Not a near term expectation in my book. Nice long term dream.

Flippers are gone. No pump and dump, so quiet until major news. PR on HemaX safety trial green light was significant to company being able to move forward, but not guarantee of success. Big volume will need new money which will need bigger news.

Good morning Sage. Stock prices are dependent on a lot of factors. Some overvalue companies, some undervalue companies and some are at the prey of organized manipulation. Check out PPCH stock price variance over the past 5 days. 1,000% price change low to high as a result of a $4,000 ad campaign with the right group. No drastic change in company over that period, just a well orchestrated release, repackaging of info that started what might be a pump and dump or what might be a new price base because of sector potential.

I can't tell you where RGBP is. I definitely feel that if the plan of RGBP spin off with immediate follow up of HemaX FDA approval had occurred as planned last year, we wouldn't be in this price range. Unfortunately, it must be noted that the CEO David Koos has a troublesome business past with creating companies that didn't perform according to the expectations of PRs released. It may be a while before that past can be shed. The price can change very quickly with even one large investment company as the avg shares traded here daily amount to less than $50,000/day.

Sustained, concrete facts and progress - the FDA approval of HemaXellerate to human trials and the auto designation of Orphan Drug status will definitely impact this stock price, but right now we haven't had the big outside investment money and our past is not pretty, so the price is lacking. Ichims remember are less than 2 months hired, big money is cautious and wants the facts and performance which Koos cannot give, so until RGBP lays new ground with the Ichims living up to their name and patents get noticed as being important. Remember, this is a penny stock, a small fish in a big ocean of thousands of scientists. Big money doesn't drudge the penny stock charts I wouldn't think, but they will keep their eyes on patents and FDA clinical trial approvals. I believe that is when the game will change and IF, IF RGBP can follow through and get HemaX and dCellVax or another treatment to human trials sometime in 2015, we might not be in penny land much longer.

CTCFL is yet another possible development that was previously researched and then acquired by scientist T. Ichim. Yet another possibility down the road, maybe sooner rather than later we don't know.

The reality though, is with the scientists on board that discovered and researched some of these new treatments, they don't take away possibilities, but only add possibilities to the pipeline and Koos put time frames on their stock awards so that this can't be strung out indefinitely without negative consequences to the pockets of the scientists, so I think the next year is going to be a lot more promising than last year turned out to be.

CT, that would be great, but nowhere do I recall BMSN/REGEN stating that the animal or human cell studies were performed in or according to GLP standards.

They said the experiments were enough to begin writing an IND, i.e. they have proof of concept of efficacy. But what about actual safety studies based on the recent silencing of the dendritic cells? After all, if the IND is to silence the dendritic cells, you still have to prove not only that you can silence the cell, but that it is safe to do so.

I believe the efficacy and proof of concept studies most likely do not qualify for the safety protocol studies according to GLP.

I've been reading the PRs closely, so I don't think you will find that wording or confirmation anywhere. Many of the PRs were written to give positive vibes without confirming the meat and potatoe details necessary for going forward.

So I'm not planning on that announcement - Green light for human trials yet, but rather something less spectacular, but still significant indicating that it will move forward. If dCellVax were getting close or closer than HemaX, then we would have had a PR about responding to x and y FDA review of IND.... Instead, the recent PR about filing patent for NR2F6 target mentions being able to do parallel studies for NR2F6 and dCellVax, which to me indicates that they might have found something new and possibly more effective, potent and need to do testing before tying off the initial dCellVax IND.

I followed a stock that had a specific treatment for cancer drug application that included a filter and had submitted human trial phase data for final FDA approval of the treatment itself when they found a better way to build the filter which eliminated a lot of the sub par side effects. They added the new filter improved data to their previous data in hopes of getting the overall treatment approved. The FDA turned them down, saying they had to restart from scratch with the new filter and re perform all the safety and human trials since the filter had changed -uugggh. Like building a car and adding new tires and saying now we can't approve the car since the tires are new, even though the new tires increase performance for safety.... Hence, if RGBP has discovered something new, more effective or believes a combo application between dCellVax and NR2F6 target is a better, more potent application, they may wait to do studies of the combo treatment and modify the dCellVax IND with new data, since once the IND is finalized for human clinical trials, I don't think you can change your protocols.

In the spirit of CT's posting, here's a posting of PRs issued since Jan 14,2015. Notice anything different in 2015?

Well, check the dates. So far we are getting a PR before the market opens nearly every week on schedule. Challenge anyone to find that type of planned news release over the past 2 years. There is a new plan in action at RGBP and it will be developed and released over time. My gut feeling we get another PR on Friday at least to confirm payment of divvy:

Regen Receives Green Light From FDA to Proceed With GLP Safety Study in Support of Its HemaXellerate Investigational New Drug ApplicationMarketwired(Tue 8:30AM EDT)
REGEN BIOPHARMA INC Files SEC form 8-K, Unregistered Sale of Equity Securities, Entry into a Material Definitive AgreEDGAR Online(Tue, Mar 10)
Regen BioPharma Acquires Issued Patent and Preclinical Data Package for Targeting Cancer Stem CellMarketwired(Tue, Mar 10)
Regen BioPharma Inc. Files Patent Application for Treatment of Myelodysplastic Syndrome Utilizing Gene Silencing TherapyMarketwired(Tue, Mar 3)
Regen BioPharma Inc. Announces Preferred Stock DividendMarketwired(Tue, Feb 24)
REGEN BIOPHARMA INC Files SEC form 8-K, Other EventsEDGAR Online(Tue, Feb 24)
Regen BioPharma, Inc. Comments on dCellVax Cancer IDO-Targeting Technology in Relation to Bristol Myers Squibb-Flexus Biosciences, Inc. AnnouncementMarketwired(Tue, Feb 24)
Regen BioPharma, Inc. Expands Management Team With the Addition of New CFO Todd CavenMarketwired(Tue, Feb 17)
REGEN BIOPHARMA INC Files SEC form 8-K, Unregistered Sale of Equity Securities, Material Modification to Rights of SeEDGAR Online(Tue, Feb 17)
REGEN BIOPHARMA INC Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Fri, Feb 13)
REGEN BIOPHARMA INC FinancialsEDGAR Online Financials(Wed, Feb 11)
REGEN BIOPHARMA INC Files SEC form 8-K, Unregistered Sale of Equity SecuritiesEDGAR Online(Mon, Feb 9)
REGEN BIOPHARMA INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, Feb 4)
REGEN BIOPHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to Articles of Inc. orEDGAR Online(Thu, Jan 22)
Regen BioPharma, Inc. Provides Update on Company's Progress and Areas of Specialization for 2015Marketwired(Wed, Jan 14)

GM and Mr. Mando, I believe today's PR puts us in the speculation of possible scenarios stickied to solidly somewhere in #4 with elements of 5 and 6 as well still possible.

Nice to feel that's it's not a total pipe dream to think of at least 2 human clinical trials could be underway before the end of 2015 with one an automatic Orphan Drug status candidate.

No, the reference was to BMSN at .0006-.0007 is hardly a huge purchase.

Only in between the lines. The PRs dealing with IND of dCellVax mentioned something like they expected dCellVax to have to go through a process and timeframe similar to HemaX.

I remember commenting at the time that that was not good news and probably indicated a known delay for dCellVax since they are both cell based treatments and I doubt that if they didn't meet GLP protocol for HemaX for experiments done after FDA conversations, it is not probable that they did for dCellVax.

Another reason we haven't heard much about dCellVax other than "it's in development" after the IND - no PR on feedback from FDA, 2nd round of questions etc. Why go into that and issue a negative PR that 'we are in discussions with FDA over safety procotols for dCellVax that will need to be performed before FDA approval'. Not a great statement, but something I think they knew upon submission, but wanted to file anyway to get it on the books.

That's why clearance today for HemaX is significant and I think will follow with a PR in not to distant future on same for dCellVax. Knowing this along with conference interest over C. Ichim presentation on NR2F6, suddenly puts a possible triple winner in the works with the possibility that any one of the three could be a home run.

And I bought another 2700 shares today, so I will be able to say whether buying between the 10th and 20th acquired Dividend rights or not as some have speculated. (Not that it will help anyone in this situation at that point )

Thanks CT. General glance shows that for some reason, the animal studies were not completed in a way, before or after IND filing to satisfy the FDA.

The reasons why we do not know, a) incompetence, b) initial animal studies were done by scientists I believe from another country that might have conducted them for research, not intending as necessary for IND study, but research only, c) miscommunication between BMSN and FDA - who knows.... we don't.

But what is clear, it wasn't simple and took someone else from the outside other than Koos to get it straightened out. I think at some point it became even clear to Koos that BMSN/RGBP was not going to go forward with only him on the payrolls. If Koos wanted to succeed, he was going to have to let others take over various aspects of the company and development.

And, right now, some of that has taken place. I'm happy about that.

So, here we are, 2 years after IND will only new safety trials between FDA human clinical trials and automatic Orphan Drug Status with manufacturing and the human trial protocol itself already in place.

Even if safety testing takes 4 months total, we are looking at potential commencement of human trials with orphan drug status in July! Then let the fireworks begin.

Ditto. I wasn't expecting HemaXellerate to be the next news piece. To me this is a bonus and I don't think all the restructuring was done to accommodate the announcement of HemaX getting green light to proceed to safety trials.

Having HemaX back in the ball game and green lighted to proceed I think is one good part to a larger puzzle and they didn't need to hire Cavens to write a PR on HemaX. Koos could have done that himself. Everything points to a bigger picture taking place.

Hope has returned and this is a concrete, positive, objective step forward.
Finally.

Agreed. Expect a planned PR in the next 2 weeks to update us or give news on dCellVax.

Then maybe a PR on NR2F6 3rd Gen or IND or safety trials in prep for IND.

Then an update on mid safety trial positive results for HemaX...

My point being, in 2013 we were tied to HemaX only and waiting on news for that. Because of the delays, we now have multiple treatments that can make the news and if, 3-4 months from now, there is official FDA approval for human trials with Orphan Status, then those looking into RGBP will also see dCellVax in development, NR2F6 in development...

I think it will be a lot more fun in the 2nd half of 2015 than the second half of 2014.

For all those that said they believed in the science, well, we are getting close to the science being the main propulsion behind the company and Koos maybe taking a back seat.

At this point, it is clear that such a response is not grounded in facts, but for some other reason and all should take note.

Anyone can go back and read the PRs. The ups and downs are clear.

Feb 2013 IND for Hema
2014 FDA requests further safety studies on rats with cancer under different circumstances than the safety studies submitted.
2014 spin off of RGBP in anticipation of FDA approval
Setback, as FDA approval manufacturing and human trial protocol for HemaX, but rejects safety study data on GLP principles (not that the data was bad, but that the data was not acquired in a manner that met the criteria of FDA GLP). OUCH, that was unexpected setback that dropped price of both RGBP and BMSN because it showed a lack of understanding and/or competence with Koos and how things were done.

Since I think as early as May 2014, Koos and Co were most likely arguing back and forth with FDA over the safety data and finally we had the PR where Ichim I think was quoted as saying they "were happy" with the high standards of the FDA as meeting the new criteria will make HemaXellerate I safety tests even more effective in the development of applying HemaX to other cancers. But then months passed without any agreement on what the new safety tests had to do and under what GLP protocol.

That was not encouraging.

Now in 2015, since Jan, we have 2 scientists on board full time, a wheeler/dealer PR and merger man to bring in money and TODAY, for the first time, affirmation from FDA and RGBP on agreed upon NEW SAFETY test protocol for HemaX that most likely will facilitate new safety testing for dCellVax and maybe NR2F6 tests so that within 2015, we might anticipate the possibility of 3 FDA IND approvals for HemaXellerate I, dCellVax and NR2F6.

That is the 2015 hope I need. I can wait for the price to grow gradually and once the 1st Qtr financials hit with half a million or more in the bank vs 0 at the end of Jan and RGBP now has a CEO, CFO, and 2 scientists as directors of development, instead of one Koos playing all parts, the chance for outside interest, whether capital investors or larger pharma, has increased significantly.

For the flippers, today's PR might now give a lot of fuel, since many of the flippers of old have gone their way and you will need news of FDA approval for clinical trials after these safety tests to have the drastic moves you are looking for, but for the longs that have been on a roller coaster seemingly stranded in a car at the bottom of a loop, today's news in light of all the other 2015 PRs and developments, is a shot in the arm that what we anticipated in 2014, now appears to have traction to take place in 2015 and along the way, we have also received a couple of divvys for our patience and pain.

One last point, the very fact that we received a PR this morning, is further encouragement that there is a planned release of information in place and I think more good news coming over the next month. Maybe a PR on the 20th, or maybe next week, but I am very encouraged by the thought of regular updates along the way, keeping interest and showing progress as well as transparency.

Now I have to get back to my work.

Let's address the significance of the 2 previous PRs you cited in light of today's PR since maybe others are new and do not have the history correct.

BMSN filed the IND for HemaXellerate in Feb 2013 with a timeline to get to human trials and complete them before the end of 2015.

In the PR you cited in 2014, BMSN had spun off RGBP I believe in anticipation of full FDA approval of HemaX to go to trial, but they only got 2/3 of the way, with manufacturing approval and human trial approval, but rejection of previous safety studies done (including those done after FDA request on rats with various conditions - THIS WAS A BIG SETBACK.

Since that PR in 2014, all we had was that Koos and Co were in contact, "discussions" with FDA over agreed upon new safety study protocols acceptable to FDA in light of a future human trial approval for HemaX (along with similar safety protocols that would be needed for dCellVax.

Up until today, we didn't know whether or when these safety trials would take place. Today's PR is not the Grand Slam some may have been looking for, but is a very happy and GREEN PR to me that the clog is now out of the wheel and we move forward - a big base hit and I think we can anticipate another base hit within a few hits announcing safety trials for dCellVax to take place as last step for its IND review as well.

Today's PR is very significant - very hopeful, especially in light of all the other developments occurring in 2015. I LIKE IT!

After all, Todd Cavens has to do something to earn his monthly salary, right? And if he put all the news into one PR, he might not have much to show for the rest of the month.

This way it becomes more of a challenge and guessing game to flip as you can't expect 3 months to go by without an update.

I'm expecting/hoping for a PR this week.

If the pattern of Jan/Feb holds up and this is a planned step by step unveiling of things in development and reasons behind the hiring / divvy, then I would expect a PR every 2 weeks or so.

I'll be looking for it along with you. I'm hoping 2015 solidifies the process of development. I'm not looking for immediate buyout, not against it, but am hoping for actual concrete progress that will warrant hope for the future. Recent PR states: "Currently Regen is using gene silencing to block NR2F6 in cancer stem cells. The acquisition of the CTCFL intellectual property allows for performing experiments in parallel, thus significantly reducing developmental costs while doubling the probability of success."

That indicates time, not an immediate gratification of FDA news.

I will be happy if within 2015 we have FDA approval for one clinical trial of any of the treatment candidates, I will remain hopeful if we get news on safety trials going forward within the next month for any and will be estatic if we get news on two or more INDs actually progressing to clinical trials within 2015.

I not looking for a rocket ship to the moon leaving tomorrow, I would be very content to see $1 by the end of the year, but whether this goes up like a rocket tomorrow or takes off and lands 5 times from here before reaching the goal, I have no idea and no crystal ball.

As I've said before, with the hiring of Ichims and Caven, this is swim or sink time I think. If RGBP is no further along with actual milestones and time frames set by the end of the year for HemaX, dCellVax and NR2F6 filing, then we might not ever take off. Right now, we've been fed indications of life and hope.

I will have to wait, as everyone else, to see what fruit it bears.

No problem, uplisting will come with progress which is our main concern. Shareholder value and stock price will increase with validated treatments that get FDA approval for human clinical trials. Once that occurs, any number of positive things might occur regardless of what exchange this is on.

Just one point. Can you clarify for me how Koos has been making millions? There is no cash revenue, so the only way for Koos to cash in is by selling shares, right? And as a publicly filing company, wouldn't any shares Koos sells have to be declared and filed, showing up on an Insider's Sales Report?

Or is it different for Pinks?

How is Koos raking in money?

Dream land right now. Reading this, company needs minimum $4 million in equity and $2-$3 price.

Let's take this in steps. This isn't going to jump from pinks to AMEX and I doubt (I hope) that is the main focus right now. Right now, let's focus on a significant development that gives us a timetable for where treatments are at, money in the bank to pay for development and a new IND targeting NR2F6.

And for those not wanting to reread the complete PRs Mr. Mando has kindly reposted, here are 3 short excerpts that show a clear thread of where the new promising technology is aimed: "cell differentiation" or the ability to treat multiple forms of cancer by coaxing the stem cells which create tumors to change into normal cells. Rather than having to "kill cancer cells", by gene silencing technologies, the stem cells change into non threatening cells. In Jan, the PR talked of a more potent, 2nd Generation gene silencing compound and in March, a new patent application. In January Koos stated they needed to verify the best, most potent compound before filing an IND since once filed, you don't change the treatment, so you want your ducks in order. Whether or not they've verified enough to go forward with an IND we don't know, but that is a clear direction for this new focus on NR2F6 and related studies.

That's where it gets tricky. We've been expecting such news for months only to get the PR in January that they still hadn't clarified an agreed upon safety protocol with the FDA, with whom they had previously stated they had been on the phone with discussing such issues.

I haven't gone back to look, but I believe that was last year around October or possibly earlier. Which begs the question, "Why?" Why, after many months, were they not able to design even a safety test protocol that would meet FDA approval? Does it have to do with FDA not being sure or clear because of the newness of the field (if so, then why are others getting approvals to move forward?), or does it have to do with Koos & company?

That's the red flag side of all this - HemaX was on a previous timeline to have concluded Phase I human trials in 2015, but here we are in 2015 without even an established protocol for new safety tests as of Jan. That's why I had given up most hope. My renewed outlook, as stated, is in the Ichims whom I'm assuming have integrity (via the testimony of their life stories) and would not become employees under Koos if they knew RGBP was a sham/scam scheme with no realistic hope of success.

That's also why I believe NR2F6, which depends on C. Ichim 10 years of research in field and her brother's patent regarding CTCFL, which they say are such that parallel studies can advance both, are now at the forefront of RGBP moving forward and maybe bypassing HemaX on hold.

Either way, if my speculation is grounded, we should have clarity through one or more PRs by end of March-mid April.

And with Cavens on board, I would expect some type of PR update bi-monthly or monthly regarding RGBP developments in order to continue interest in the hope of bringing in money.

It's got to get better with 3 others working full time than with Koos alone.

Everything happens for a reason. If you were in Koos' shoes and paying yourself $300-$400K/yr on paper, why would you suddenly cut your own salary in light of new positive developments regarding NR2F6, new patents...

Afterall, Koos didn't take the cut when HemaX wasn't approved or during the silence of no news for months. It coincides with positive news, so no reason for Koos to see the need himself. The reduction in salary, most logically, is due to a reason beyond Koos.

Another complete speculation is that Inventor1 has been unusually quiet throughout the 2015 PR developments with only a very occasional short post.

I actually see this as a possible positive sign that there might be some type of agreement/major news development to take place within March/April timeframe (everyone selling today is betting on the divvy being an isolated incident unto itself whereas I think the divvy only makes sense in light of something else - 2 very different takes) because the developments are under a quiet period type mandate.

This is hopeful thinking I know, but at the moment I'm more hopeful than I was 2 months ago. It might all be for naught if RGBP is nothing more than a rebranded BMSN as others point out, but I'm thinking that the pace and events of 2015 thus far point to the news not yet being over and on or after March 20th (could always be before), we will have another PR to shed more light on the reason of the Preferred A shares.

Stepping aside from the minute by minute broadcast of a penny stock's performance, something struck me this morning. With the hire of Ichim's as employees and Koos hiring himself as CEO, it escaped me at the time, but didn't Koos take a pay cut in the process? His new salary is $180,000/yr.

Seems to me that somewhere before he was paying himself $300,000-$400,000 on paper or is that still the case under BMSN? Can anyone else comment on this?

My thought is this: if in fact Koos cut a pay cut and stabilized his salary, about the only reason I can think of is that he was pressured into doing it by someone outside in return for a future agreement, i.e., company B agrees in principle to work with RGBP only if the IP and the scientists (Ichims) are directly under RGBP with agreed upon costs.

As others have said, we believe in the science while having doubts about Koos. An outside partner may see it the same way. All hires were for 3 years and company B might have proposed: We will invest/partner with RGBP under these conditions: the scientists work on project X full time as employees, Koos takes a salary cut and we invest X resources with a 3 year timeline of bringing x,y,z to a point of human trials for a % cut of x,y,z. If it does not make it to trials within such and such a time frame, the deal is off....

Others comments.

AIMO

That's what I thought until Flexus was bought for potentially 1.2 billion based on potential product pipeline that was not yet an IND.

Flexus had one drug in production that was not a 1.2 billion dollar value and the PR on the purchase was based on non IND treatments in development.

So, while FDA approval I think is critical for trading PPS gaining true roots, I'm now intrigued by the possibility of the recent cell based buyouts based on potential treatments, so IP is important and RGBP definitely has more value on paper today than last year. Now, that doesn't mean the price will reflect it.

As I've said, my position is based on development and my hope that 2 full time scientists and money to perform trials, will change the scenery. Before, we had grass seed sitting on the shelves, trying to predict a miraculous green lawn suddenly sprouting. Now we've got landscape professionals actually planting the seeds, watering and caring for the seed, so my expectations for a green lawn have gone up.